Acadia Pharma (ACAD) Misses Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $27.74 +0.22%
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26).
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Frequency Electronics (FEIM) Tops Q1 EPS by 12c
- RUM Group to raise Northern Data stake to ~98% via share purchase
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
